Tenaya Therapeutics, Inc. cotiza a 0.57 USD y tiene una capitalización bursátil de $127M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.09 | $-0.09 | $-0.12 |
| Estimado | $-0.09 | $-0.07 | $-0.09 | $-0.12 |
| Sorpresa | — | -28.6% | +0.0% | +0.0% |
| Métrica | TNYA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -73.5% | -40.4% | -33.1% |
| ROA | -61.7% | -32.0% | -29.6% |
| Current Ratio | 6.84 | 2.84 | +4.00 |
| Debt / Equity | — | 0.28 | — |